ยาลดน้ำหนักในปัจจุบัน
Abstract
No available
References
National Institutes of Health, National Heart, Lung, and Blood Institute: Clinical guidelines on the identification, evaluation, and treatment of overweight and
obesity in adults. Bethesda, MD: US Department of Health and Human Services, 1998.
สำนักงานสำรวจสุขภาพประชาชนไทย. รายงานการสำรวจสุขภาพประชากรโดยการตรวจร่างกายครั้งที่ 4 พ.ศ. 2551-2 โดย: นายแพทย์วิชัย เอกพลากร, บรรณาธิการ. นนทบุรี: เดอะกราฟิโกซิสเต็มส์จำกัด; 2553:. หน้า 127-34.
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342-362.
Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med2005;142:532-46.
Padwal RS, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Database of Systemic Reviews 2004;(3):CD004094.
Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-203.
Franz MJ, VanWormer JJ, Crain AL, et al. Weightloss outcomes: a systemic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007;107:1755-1767.
Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373(1):11-22.
Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE
maintenance randomized study. Int J Obes (Lond) 2013;37:1443-51
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE
diabetes randomized clinical trial. JAMA 2015; 314(7):687-99.
Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe
obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 2016 Mar 23. [Epub ahead of print]
Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled
trials. Obes Rev 2011;12(5):e338-47.
Allison DB, Gadde KM, William Timothy Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial
(EQUIP). Obesity 2011;20:330-42.
Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.Lancet 2011;377:1341-52.
Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release
phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:
-308.
Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363(3):245-56.
Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obeseand overweight adults: the BLOSSOM trial. J Clin
Endocrinol Metab 2011;96(10):3067-77.
OûNeil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOMDM
study. Obesity (Silver Spring) 2012;20(7):1426-36.
Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605.
Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/ bupropion SR combination therapy as an adjunct to behavior modification: the
COR-BMOD trial. Obesity 2011;19(1):110-20.
Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/ bupropion SR on weight and obesity-related risk factors (COR-II). Obesity
;21(5):935-43.
Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/ bupropion sustainedrelease combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36(12):4022-9.
Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59(2): 151-84.
Downloads
Published
How to Cite
Issue
Section
License
The content and information in the articles published in Thai JPEN วารสารโภชนบำบัด, are the opinions and responsibility of the authors directly. The editorial team is not obliged to agree or take any responsibility.
All articles, content, figures, etc. that have been published in Thai JPEN วารสารโภชนบำบัด are the copyright of Thai JPEN วารสารโภชนบำบัด. If any person or organization require distribution of all or any part of them, please send the request for the written permission from Thai JPEN วารสารโภชนบำบัด only.
